FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904334875> ?p ?o ?g. }

• W2904334875 endingPage "126" @default.
• W2904334875 startingPage "119" @default.
• W2904334875 abstract "Limited treatment data are available for hepatitis C virus (HCV) in sub-Saharan Africa, especially for genotype 4. Our objective was to establish the safety and efficacy of ledipasvir-sofosbuvir for chronic HCV genotype 1 or 4 infection in adults in Rwanda.We did a single-arm trial to evaluate the safety and efficacy of ledipasvir-sofosbuvir in Rwandan adults with chronic HCV infection at a single study site (Rwanda Military Hospital, Kigali, Rwanda). We enrolled individuals aged 18 years or older with HCV genotype 1 or 4 infection and a plasma HCV RNA concentration of more than 1000 IU/mL at screening. All participants were given ledipasvir (90 mg) and sofosbuvir (400 mg) in a single combination tablet once daily for 12 weeks. We established HCV genotype using an Abbott platform, and HCV subtype with PCR amplification. The primary endpoint was the proportion of participants with a sustained virological response 12 weeks after therapy (SVR12). All patients enrolled in the study were included in the primary endpoint analyses. This study is registered with ClinicalTrials.gov, number NCT02964091.300 participants were enrolled between Feb 6, 2017, and Sept 18, 2017, and the follow-up period was completed on March 1, 2018. On genotyping, 248 (83%) participants were reported as having genotype 4, four (1%) genotype 1, and 48 (16%) both genotype 1 and genotype 4. Subsequent viral sequencing showed all participants actually had genotype 4 infection with subtype 4k (134 [45%]), subtype 4r (48 [16%]), subtype 4q (42 [14%]), and subtype 4v (24 [8%]) predominating. Overall, 261 (87%, 95% CI 83-91) participants achieved SVR12. In participants with genotype 4r, SVR12 was observed in 27 (56%, 95% CI 41-71) participants versus 234 (93%, 90-96) individuals with other subtypes. There were no drug-related treatment discontinuations due to ledipasvir-sofosbuvir. The most common adverse events were hypertension (97 [32%]), headache (78 [26%]), dizziness (61 [20%]), and fatigue (56 [19%]). There were six serious adverse events; none were assessed to be due to the study drug. 296 participants had data for pill counts at week 4 and 8; 271 (92%) had 100% adherence and only one (<1%) had an adherence of less than 90%.This is the first large-scale prospective study reporting direct-acting antiviral outcomes in sub-Saharan Africa. The high adherence and treatment success without intensive support measures or highly specialised clinical providers, and lack of treatment discontinuations due to adverse events support the feasibility of HCV treatment decentralisation and scale-up in sub-Saharan Africa. Genotype 4r is uniquely expressed in this region and associated with high rates of treatment failure, suggesting a need for rigorous test-of-cure in clinical practice and consideration of the use of newer pangenotypic direct-acting antiviral regimens in this region.Gilead Sciences." @default.
• W2904334875 created "2018-12-22" @default.
• W2904334875 creator A5001927779 @default.
• W2904334875 creator A5012214351 @default.
• W2904334875 creator A5015407028 @default.
• W2904334875 creator A5018970834 @default.
• W2904334875 creator A5031649305 @default.
• W2904334875 creator A5037455328 @default.
• W2904334875 creator A5038756960 @default.
• W2904334875 creator A5047330733 @default.
• W2904334875 creator A5047537947 @default.
• W2904334875 creator A5048045813 @default.
• W2904334875 creator A5054466288 @default.
• W2904334875 creator A5062294366 @default.
• W2904334875 creator A5075053097 @default.
• W2904334875 creator A5081841901 @default.
• W2904334875 creator A5085620601 @default.
• W2904334875 creator A5090278740 @default.
• W2904334875 date "2019-02-01" @default.
• W2904334875 modified "2023-10-02" @default.
• W2904334875 title "Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir–sofosbuvir (SHARED): a single-arm trial" @default.
• W2904334875 cites W1571790880 @default.
• W2904334875 cites W2012709249 @default.
• W2904334875 cites W2082766572 @default.
• W2904334875 cites W2092646281 @default.
• W2904334875 cites W2124273275 @default.
• W2904334875 cites W2158714788 @default.
• W2904334875 cites W2165404627 @default.
• W2904334875 cites W2467097857 @default.
• W2904334875 cites W2467146687 @default.
• W2904334875 cites W2557685508 @default.
• W2904334875 cites W2560223644 @default.
• W2904334875 cites W2578013986 @default.
• W2904334875 cites W2611609040 @default.
• W2904334875 cites W2613218568 @default.
• W2904334875 cites W2621317001 @default.
• W2904334875 cites W2724528048 @default.
• W2904334875 cites W2735409348 @default.
• W2904334875 cites W2735511229 @default.
• W2904334875 cites W2743977148 @default.
• W2904334875 cites W2750060262 @default.
• W2904334875 cites W2761028974 @default.
• W2904334875 cites W2776526568 @default.
• W2904334875 cites W2795659653 @default.
• W2904334875 cites W2806304753 @default.
• W2904334875 doi "https://doi.org/10.1016/s2468-1253(18)30382-0" @default.
• W2904334875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30552056" @default.
• W2904334875 hasPublicationYear "2019" @default.
• W2904334875 type Work @default.
• W2904334875 sameAs 2904334875 @default.
• W2904334875 citedByCount "61" @default.
• W2904334875 countsByYear W29043348752019 @default.
• W2904334875 countsByYear W29043348752020 @default.
• W2904334875 countsByYear W29043348752021 @default.
• W2904334875 countsByYear W29043348752022 @default.
• W2904334875 countsByYear W29043348752023 @default.
• W2904334875 crossrefType "journal-article" @default.
• W2904334875 hasAuthorship W2904334875A5001927779 @default.
• W2904334875 hasAuthorship W2904334875A5012214351 @default.
• W2904334875 hasAuthorship W2904334875A5015407028 @default.
• W2904334875 hasAuthorship W2904334875A5018970834 @default.
• W2904334875 hasAuthorship W2904334875A5031649305 @default.
• W2904334875 hasAuthorship W2904334875A5037455328 @default.
• W2904334875 hasAuthorship W2904334875A5038756960 @default.
• W2904334875 hasAuthorship W2904334875A5047330733 @default.
• W2904334875 hasAuthorship W2904334875A5047537947 @default.
• W2904334875 hasAuthorship W2904334875A5048045813 @default.
• W2904334875 hasAuthorship W2904334875A5054466288 @default.
• W2904334875 hasAuthorship W2904334875A5062294366 @default.
• W2904334875 hasAuthorship W2904334875A5075053097 @default.
• W2904334875 hasAuthorship W2904334875A5081841901 @default.
• W2904334875 hasAuthorship W2904334875A5085620601 @default.
• W2904334875 hasAuthorship W2904334875A5090278740 @default.
• W2904334875 hasConcept C104317684 @default.
• W2904334875 hasConcept C126322002 @default.
• W2904334875 hasConcept C135763542 @default.
• W2904334875 hasConcept C159047783 @default.
• W2904334875 hasConcept C185592680 @default.
• W2904334875 hasConcept C203092338 @default.
• W2904334875 hasConcept C2522874641 @default.
• W2904334875 hasConcept C2775999097 @default.
• W2904334875 hasConcept C2776408679 @default.
• W2904334875 hasConcept C2776455275 @default.
• W2904334875 hasConcept C2778390639 @default.
• W2904334875 hasConcept C2780040827 @default.
• W2904334875 hasConcept C31467283 @default.
• W2904334875 hasConcept C535046627 @default.
• W2904334875 hasConcept C55493867 @default.
• W2904334875 hasConcept C71924100 @default.
• W2904334875 hasConcept C90924648 @default.
• W2904334875 hasConceptScore W2904334875C104317684 @default.
• W2904334875 hasConceptScore W2904334875C126322002 @default.
• W2904334875 hasConceptScore W2904334875C135763542 @default.
• W2904334875 hasConceptScore W2904334875C159047783 @default.
• W2904334875 hasConceptScore W2904334875C185592680 @default.
• W2904334875 hasConceptScore W2904334875C203092338 @default.
• W2904334875 hasConceptScore W2904334875C2522874641 @default.
• W2904334875 hasConceptScore W2904334875C2775999097 @default.

• next